M2017 First Line Treatment of Inoperable Pancreatic Adenocarcinoma with Lipid Complexed Paclitaxel Nanoparticles (EndoTag-1) Plus Gemcitabine Compared with Gemcitabine Monotherapy: A Prospective Randomised Controlled Phase II Study

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomised Controlled ◽

First-line treatment of inoperable pancreatic adenocarcinoma with lipid complexed paclitaxel nanoparticles plus gemcitabine compared with gemcitabine monotherapy. A prospective RCT - phase II study

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.4618 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 4618-4618 ◽

Cited By ~ 5

Author(s):

M. Löhr ◽

S. Haas ◽

W. Bechstein ◽

M. Karrasch ◽

A. Mescheder ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM)

European Journal of Cancer ◽

10.1016/j.ejca.2014.09.015 ◽

2014 ◽

Vol 50 (18) ◽

pp. 3116-3124 ◽

Cited By ~ 15

Author(s):

Isabelle Trouilloud ◽

Anne-Claire Dupont-Gossard ◽

David Malka ◽

Pascal Artru ◽

Mélanie Gauthier ◽

...

Keyword(s):

Dose Rate ◽

Phase Ii ◽

Phase Ii Study ◽

Fixed Dose ◽

Line Treatment ◽

First Line ◽

Metastatic Pancreatic Adenocarcinoma ◽

Fixed Dose Rate ◽

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

European Journal of Cancer ◽

10.1016/j.ejca.2020.05.018 ◽

2020 ◽

Vol 136 ◽

pp. 25-34

Author(s):

Yves Rinaldi ◽

Anne-Laure Pointet ◽

Faiza Khemissa Akouz ◽

Karine Le Malicot ◽

Bidaut Wahiba ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Metastatic Pancreatic Adenocarcinoma ◽

Cancérologie Digestive ◽

Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma ( GATE 1)

International Journal of Cancer ◽

10.1002/ijc.33225 ◽

2020 ◽

Vol 148 (3) ◽

pp. 682-691

Author(s):

Eric Assenat ◽

Laurent Mineur ◽

Caroline Mollevi ◽

Evelyne Lopez‐Crapez ◽

Catherine Lombard‐Bohas ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Metastatic Pancreatic Adenocarcinoma ◽

Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study

International Journal of Gynecological Cancer ◽

10.1046/j.1525-1438.2003.13039.x ◽

2003 ◽

Vol 13 (2) ◽

pp. 130-137 ◽

Cited By ~ 9

Author(s):

T. Bauknecht ◽

A. Hefti ◽

G. Morack ◽

C. Villena-Heinsen ◽

D. Wallwiener ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study

Clinical Breast Cancer ◽

10.3816/cbc.2010.n.041 ◽

2010 ◽

Vol 10 (4) ◽

pp. 313-317 ◽

Cited By ~ 3

Author(s):

Juan de la Haba-Rodriguez ◽

Rosario González Mancha ◽

Gumersindo Pérez Manga ◽

Enrique Aranda Aguilar ◽

José Manuel Baena Cañada ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer

Lung Cancer ◽

10.1016/s0169-5002(02)00387-2 ◽

2003 ◽

Vol 39 (1) ◽

pp. 77-84 ◽

Cited By ~ 4

Author(s):

J.M Vieitez ◽

M Valladares ◽

M Gracia ◽

M Gonzalez-Barón ◽

G Martı́n ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: A phase II study

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2005.06.013 ◽

2005 ◽

Vol 23 (5) ◽

pp. 381-382

Author(s):

Donald L. Trump

Keyword(s):

Urothelial Carcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Advanced Urothelial Carcinoma ◽

Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study

European Journal of Cancer ◽

10.1016/j.ejca.2014.12.020 ◽

2015 ◽

Vol 51 (4) ◽

pp. 473-481 ◽

Cited By ~ 10

Author(s):

Maria Di Bartolomeo ◽

Andrea Ciarlo ◽

Alessandro Bertolini ◽

Sandro Barni ◽

Claudio Verusio ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Advanced Colorectal Cancer ◽

Medical Oncology ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

European Urology ◽

10.1016/j.eururo.2007.02.060 ◽

2007 ◽

Vol 52 (4) ◽

pp. 1020-1027 ◽

Cited By ~ 13

Author(s):

Giuseppe Di Lorenzo ◽

Riccardo Autorino ◽

Sisto Perdonà ◽

Michele De Laurentiis ◽

Massimo D'Armiento ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Phase Ii ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Line Treatment ◽

First Line ◽

Hormone Refractory ◽